VEGFA and renal cell carcinoma: Recently, ICI-based combinations (nivolumab plus ipilimumab) and ICIs combined with VEGF TKIs have shown remarkable efficacy in patients with metastatic RCC, and they have become the standard-of-care first-line therapies for patients with this disease.